Imperial College Healthcare NHS Trust/ UK DRI Care Research and Technology Centre at Imperial College London 

=LEFT(J108,6)

Understanding why some are more likely to experience more rapid decline allows us to provide PLWD and their loved ones with better predictions following a diagnosis and develop targeted interventions to prevent unnecessary hospitalisation

Dementia affects 944,000 people in the UK and over 50 million globally (Alzheimer’s Research UK, 2022). At any point, one in four hospital beds are thought to be occupied by people living with dementia (PLWD) (Lakey, 2009); an estimated 42% of individuals over 70 with unplanned admissions to acute services are PLWD (Sampson et al., 2009). Alzheimer’s Research UK estimates that 20% of hospital admissions in PLWD are for preventable conditions such as urinary tract infections, which are associated with increased all-cause mortality if not detected and treated early (Gharbi et al., 2019). In the absence of any current treatment to prevent or cure dementia, there is an urgent need for greater focus on the real‐world outcomes in PLWD. The UK Dementia Research Institute Care Research and Technology Centre (UK DRI CR&T) is developing ways to augment and support the delivery of dementia care and improve the quality of life of PLWD using technology. Early in 2021, we conducted initial work investigating the impact of the COVID-19 pandemic on the vulnerable elderly living in care homes (Graham et al., 2020), and extended this at a population level to examine factors influencing mortality in PLWD compared to older adults with other conditions using the Secure Anonymised Information Linkage (SAIL) Database. Using the Whole Systems Integrated Care (WSIC) Database, we would like to further expand our analysis to investigate factors influencing clinical outcomes in people living in North West London. This project will be split into three work packages: 1) Descriptive analysis of people living with dementia in North West London compared to older adults with/without frailty and other complex neurological conditions; 2) Predictive modelling of clinical outcomes in people living with dementia; 3) Integration of home-based sensor technology data from the UK DRI CR&T Minder study to validate individual-level biomarkers and support the development of the WSIC dementia dashboard. We are only requesting de-identified data for WPs 1 and 2. For WP3, we are requesting identifiable information for consented participants within the UK DRI CR&T’s Minder study, which comprises a cohort of older adults living with dementia, memory difficulties, complex neurological conditions and frailty. This study has been granted ethical approval by the London-Surrey Borders REC (IRAS ID: 257561, REC reference: 19/LO/0102, Title: Minder Health Management Study). Linking identifiable information will allow us to test whether the risk models generated at the population level are also informative at the individual level.

19/05/2022

TRE